PulseAugur
EN
LIVE 16:54:31

Eli Lilly's Obesity Drugs Fuel 48% Revenue Growth, Retatrutide Trials Show Promise

By PulseAugur Editorial · [1 sources] ·

Eli Lilly and Company reported a significant increase in its second-quarter revenue, reaching $23 billion, a 48% year-over-year growth. This surge was primarily driven by its GLP-1 drugs, Mounjaro and Zepbound, which generated $10 billion and $5 billion respectively. The company also highlighted promising results for its next-generation weight-loss drug, retatrutide, with plans to seek FDA approval in 2027 after clinical trials showed an average weight loss of over 20%. Additionally, the report touched upon a study where a cannabis-derived drug, Dronabinol, showed promise in reducing nightmares for PTSD patients. AI

RANK_REASON Company earnings report detailing significant revenue growth and promising drug trial results. [lever_c_demoted from significant: ic=1 ai=0.0]

Read on Forbes — Innovation →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

Eli Lilly's Obesity Drugs Fuel 48% Revenue Growth, Retatrutide Trials Show Promise

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Company earnings report detailing significant revenue growth and promising drug trial results. [lever_c_demoted from significant: ic=1 ai=0.0]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
product, funding
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
51 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. Forbes — Innovation TIER_1 English(EN) · Alex Knapp, Forbes Staff ·

    Eli Lilly’s Obesity Drugs Drive Massive Revenue Growth

    In this week’s edition of InnovationRx, we look at Lilly’s 2Q earnings, a cannabis-derived drug for PTSD, Apnimed’s IPO and more

RELATED ENTITIES

RELATED TOPICS